THE 60-SECOND GUIDE
LL-37
Controlled topical trial · no overall healing benefit.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
LL-37 is a human immune-defense peptide studied for antimicrobial activity and wound repair. Controlled research includes topical treatment of venous leg ulcers, but that experience does not establish benefit for systemic injections or general immune enhancement. [1]
Potential benefits
Part of human innate immune defense. Studied for antimicrobial, immune, and wound-related effects. [1]
Evidence & its limits
The 2021 trial found no significant healing advantage over placebo across the entire study population. Exploratory subgroup findings require confirmation. Both the route and setting matter: topical ulcer treatment with compression is not evidence for injected LL-37 or broad infection treatment. [1]
Risks & unknowns
Direct therapeutic use remains experimental. It can also promote inflammation or tissue injury in some contexts. [1]
Status & scope
The cited topical wound trial did not establish an overall healing benefit. It does not validate systemic injections or unrelated immune-health claims. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- Exploratory randomized topical LL-37 trial, 2014
- HEAL LL-37 phase IIb randomized trial, 2021
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.